PACB · XBRL financial data

Pacific Biosciences of California financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (PACB's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue from contracts with customers	56	—	39	36	40	—	37	40	38	—	37	39
Cost of revenue	38	49*	28	30	30	29*	39	25	23	28*	24	26
Gross profit	18	—	11	6	10	—	(1)	15	16	—	13	13
Research and development	48	45*	43	38	26	27*	29	23	23	23*	20	23
Selling, general and administrative	43	46*	44	46	44	42*	40	36	31	34*	31	33
Total operating expenses	100	97*	93	182	74	163*	428	60	55	58*	21	57
Operating income (loss)	(82)	(88)*	(81)	(176)	(64)	(153)*	(429)	(45)	(39)	(41)*	(8)	(45)
Interest expense	4	4*	4	4	4	3*	2	2	2	2*	2	2
Other income (expense)	9	8*	7	6	7	4*	4	5	3	3*	2	2
Income tax expense (benefit)	(11)	(1)*	0	0	0	0*	(0)	0	0	0*	0	0
Net income (loss)	(67)	(82)*	(78)	(173)	(61)	2*	(426)	(42)	(38)	(40)*	(8)	(45)
Earnings per share, basic USD per share	(0.26)	(0.31)*	(0.29)	(0.64)	(0.22)	0.01*	(1.44)	(0.14)	(0.13)	(0.13)*	(0.03)	(0.14)
Earnings per share, diluted USD per share	(0.26)	(0.31)*	(0.29)	(0.64)	(0.22)	—	(1.44)	(0.14)	(0.13)	(0.13)*	(0.03)	(0.14)
Weighted average shares, basic millions of shares	255	267*	270	272	273	283*	297	300	301	302*	306	311
Weighted average shares, diluted millions of shares	255	267*	270	272	273	338*	297	300	301	302*	306	311

Fiscal quarters (PACB's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	386	180	77	100	78	55	59	55	56	64	56	61
Short-term investments	382	452	485	410	393	335	285	260	242	216	220	176
Marketable securities	—	465	—	—	—	—	—	—	—	—	—	—
Marketable securities, non-current	—	96	—	—	—	—	—	—	—	—	—	—
Accounts receivable	30	37	30	32	29	28	32	32	31	35	29	31
Inventory	68	57	67	69	66	59	54	54	53	49	51	61
Prepaid and other current assets	15	17	17	17	17	19	15	12	12	11	13	10
Total current assets	882	742	677	628	584	496	445	413	394	375	370	339
Property and equipment, net	40	36	37	35	32	31	25	23	22	24	24	27
Right-of-use asset	35	33	31	22	17	16	44	44	43	42	41	40
Goodwill	464	462	462	369	369	318	318	318	318	318	318	318
Total assets	1,898	1,746	1,670	1,509	1,450	1,260	861	825	803	784	782	752
Accounts payable	16	15	21	17	12	17	14	15	16	21	14	19
Accrued liabilities	35	46	22	22	19	23	29	27	29	34	34	30
Total current liabilities	184	95	73	78	60	66	67	60	63	73	65	69
Lease liability, non-current	34	32	29	20	17	15	50	52	54	57	59	60
Total liabilities	1,135	1,045	1,021	1,017	997	754	769	764	767	779	780	785
Accumulated deficit	(1,757)	(1,839)	(1,917)	(2,091)	(2,151)	(2,149)	(2,575)	(2,617)	(2,655)	(2,695)	(2,704)	(2,748)
Total stockholders' equity	764	701	649	493	453	507	92	61	36	5	2	(33)
Total liabilities and equity	1,898	1,746	1,670	1,509	1,450	1,260	861	825	803	784	782	752
Common shares outstanding (cover page) millions of shares	267	268	272	273	274	298	300	300	302	302	311	311

Fiscal quarters (PACB's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(67)	(82)*	(78)	(173)	(61)	2*	(426)	(42)	(38)	(40)*	(8)	(45)
Stock-based compensation	20*	17*	20	17*	18*	16*	9	12*	11*	10*	4	9*
Net cash from operating activities	(65)*	(58)*	(76)	(54)*	(45)*	(31)*	(44)	(29)*	(19)*	(19)*	(45)	(36)*
Purchases of property and equipment	1*	2*	4	1*	(1)*	2*	1	1*	(0)*	1*	3	2*
Net cash from investing activities	242*	(67)*	(34)	77*	23*	58*	45	25*	19*	26*	36	40*
Proceeds from issuing common stock	0*	(174)*	0	0*	0*	0*	—	—	—	year only	—	—
Net cash from financing activities	(1)*	(82)*	7	(0)*	1*	(50)*	2	0*	1*	0*	1	0*
Net change in cash	176*	(206)*	(103)	22*	(22)*	(23)*	3	(4)*	2*	7*	(7)	5*

SIC 3826 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3826 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Pacific Biosciences of California	61	39	(36)*	310.8M	6.7 quarters	Q2 FY26 10-QJun 30, 2026
Senseonics Holdings	45	14	(30)*	52.9M	4.7 quarters	Q2 FY26 10-QJun 30, 2026
Mesa Laboratories	31	60	15	5.6M	—	Q1 FY27 10-QJun 30, 2026
Cytek Biosciences	74	48	1.4*	130.0M	—	Q2 FY26 10-QJun 30, 2026
Alamar Biosciences	122	34	not reported	69.5M	—	Q3 FY26 10-QSep 30, 2026
Crawford United	1.9	not reported	5.7*	not reported	—	Q3 FY25 10-QSep 30, 2025
Quantum-Si	24	0.3	(18)*	not reported	6.1 quarters	Q2 FY26 10-QJun 30, 2026
Allient	42	154	14*	17.0M	—	Q2 FY26 10-QJun 30, 2026
Frequency Electronics	61	23	2.6	11.3M	—	Q1 FY27 10-QJul 31, 2026

Not investment advice. Not affiliated with the U.S. SEC.